Abstract
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease that often is associated with inflammatory bowel disease (IBD) and thats leads to destruction of the medium and large bile ducts, with a median time from diagnosis to liver transplantation or death of 20 years. In the setting of IBD, the typical cholangiographic features of segmental strictures and dilatations are nearly pathognomonic for PSC. In the absence of IBD, the diagnosis requires the exclusion of secondary causes of sclerosing cholangitis. In addition to liver failure, patients with PSC are at high risk of cholangiocarcinoma, gallbladder cancer, and, in the setting of IBD, colon cancer. Although ursodeoxycholic acid is frequently used to treat PSC, its benefit or the benefit of any other medical therapy in PSC has not been established.
| Original language | English (US) |
|---|---|
| Title of host publication | Handbook of Liver Disease |
| Publisher | Elsevier |
| Pages | 233-242 |
| Number of pages | 10 |
| ISBN (Electronic) | 9780323478823 |
| ISBN (Print) | 9780323478748 |
| DOIs | |
| State | Published - Aug 24 2017 |
Fingerprint
Keywords
- Cholangiocarcinoma
- Cholestasis
- Inflammatory bowel disease, primary sclerosing cholangitis, secondary sclerosing cholangitis
ASJC Scopus subject areas
- Medicine(all)
Cite this
Primary sclerosing cholangitis. / Bowlus, Christopher.
Handbook of Liver Disease. Elsevier, 2017. p. 233-242.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Primary sclerosing cholangitis
AU - Bowlus, Christopher
PY - 2017/8/24
Y1 - 2017/8/24
N2 - Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease that often is associated with inflammatory bowel disease (IBD) and thats leads to destruction of the medium and large bile ducts, with a median time from diagnosis to liver transplantation or death of 20 years. In the setting of IBD, the typical cholangiographic features of segmental strictures and dilatations are nearly pathognomonic for PSC. In the absence of IBD, the diagnosis requires the exclusion of secondary causes of sclerosing cholangitis. In addition to liver failure, patients with PSC are at high risk of cholangiocarcinoma, gallbladder cancer, and, in the setting of IBD, colon cancer. Although ursodeoxycholic acid is frequently used to treat PSC, its benefit or the benefit of any other medical therapy in PSC has not been established.
AB - Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease that often is associated with inflammatory bowel disease (IBD) and thats leads to destruction of the medium and large bile ducts, with a median time from diagnosis to liver transplantation or death of 20 years. In the setting of IBD, the typical cholangiographic features of segmental strictures and dilatations are nearly pathognomonic for PSC. In the absence of IBD, the diagnosis requires the exclusion of secondary causes of sclerosing cholangitis. In addition to liver failure, patients with PSC are at high risk of cholangiocarcinoma, gallbladder cancer, and, in the setting of IBD, colon cancer. Although ursodeoxycholic acid is frequently used to treat PSC, its benefit or the benefit of any other medical therapy in PSC has not been established.
KW - Cholangiocarcinoma
KW - Cholestasis
KW - Inflammatory bowel disease, primary sclerosing cholangitis, secondary sclerosing cholangitis
UR - http://www.scopus.com/inward/record.url?scp=85054235031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054235031&partnerID=8YFLogxK
U2 - 10.1016/B978-0-323-47874-8.00017-1
DO - 10.1016/B978-0-323-47874-8.00017-1
M3 - Chapter
AN - SCOPUS:85054235031
SN - 9780323478748
SP - 233
EP - 242
BT - Handbook of Liver Disease
PB - Elsevier
ER -